CASE REPORT: DYSTROPHIC-ANAGEN EFFLUVIUM OCCURRING DURING PEGYLATED INTERFERON-α-2A/RIBAVIRIN THERAPY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

TURKER KAMURAN; TAS BETUL; OZKAYA MURAT; TAS EBRU; CAGLAR AYSEL; TETIKKURT UMIT SEZA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2015 | Volume:15 | Issue:3 Page(s): 0-0

Download Full-Text

View:

318

Download:

335

Cites:

Information Journal Paper

Title

CASE REPORT: DYSTROPHIC-ANAGEN EFFLUVIUM OCCURRING DURING PEGYLATED INTERFERON-α-2A/RIBAVIRIN THERAPY

Author(s)

Keywords

ALOPECIA

INTERFERON

THERAPY

CHRONIC HEPATITIS C

Abstract

Introduction: Various types of dermatological manifestations have been reported due to hepatitis C virus (HCV) infection and antiHCV THERAPY. Some of them have been described during IFN-based therapies. PEG-IFN-a-2a/RBV combination is used as the international standard of treatment for HCV infection for a long time. The combination THERAPY yields an adverse-event profile similar to standard INTERFERON (IFN) THERAPY. Some of these adverse effects are rheumatologic, neuropsychiatric and dermatological manifestations including ALOPECIA.Case Presentation: We reported a 43-year-old woman with dystrophic anagen effluvium (DAE), rheumatoid arthritis and Hashimoto thyroiditis, which were developed under the combination THERAPY for chronic HCV infection.Conclusions: Although some cases of ALOPECIA areata (AA) and telogen effluvium (TE) were reported in literature, no case of DAE associated with PEG-INF-a-2a /RBV combination THERAPY was reported previously.

Cites

No record.

References

No record.

Cite

APA: Copy

TURKER, KAMURAN, TAS, BETUL, OZKAYA, MURAT, TAS, EBRU, CAGLAR, AYSEL, & TETIKKURT, UMIT SEZA. (2015). CASE REPORT: DYSTROPHIC-ANAGEN EFFLUVIUM OCCURRING DURING PEGYLATED INTERFERON-α-2A/RIBAVIRIN THERAPY. HEPATITIS MONTHLY, 15(3), 0-0. SID. https://sid.ir/paper/306899/en

Vancouver: Copy

TURKER KAMURAN, TAS BETUL, OZKAYA MURAT, TAS EBRU, CAGLAR AYSEL, TETIKKURT UMIT SEZA. CASE REPORT: DYSTROPHIC-ANAGEN EFFLUVIUM OCCURRING DURING PEGYLATED INTERFERON-α-2A/RIBAVIRIN THERAPY. HEPATITIS MONTHLY[Internet]. 2015;15(3):0-0. Available from: https://sid.ir/paper/306899/en

IEEE: Copy

KAMURAN TURKER, BETUL TAS, MURAT OZKAYA, EBRU TAS, AYSEL CAGLAR, and UMIT SEZA TETIKKURT, “CASE REPORT: DYSTROPHIC-ANAGEN EFFLUVIUM OCCURRING DURING PEGYLATED INTERFERON-α-2A/RIBAVIRIN THERAPY,” HEPATITIS MONTHLY, vol. 15, no. 3, pp. 0–0, 2015, [Online]. Available: https://sid.ir/paper/306899/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops